Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Blast Crisis
  • Imidazoles
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Pyridazines
  • Stem Cell Transplantation

abstract

  • Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I-positive CP-CML. Cancer 2016. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5573914

Digital Object Identifier (DOI)

  • 10.1002/cncr.30558

PubMed ID

  • 28387926

Additional Document Info